ARS Pharmaceuticals, Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| – | – | – | -293.6% | – | – | – | -1,361.2% | |
| – | +8.9% | -99.6% | +3,450.0% | +49.8% | -77.1% | -9,928.8% | – | |
| – | – | – | -20.2% | +106.5% | +58.1% | +57.4% | +52.0% | |
| – | – | – | -17.2% | +132.2% | – | – | – | |
| – | – | +95.9% | -105.5% | – | – | – | – | |
| – | -78.6% | +855.2% | -94.0% | +261.8% | -12.1% | +221.7% | -39.8% | |
| – | -78.6% | +855.2% | -94.0% | +261.8% | +43,709.0% | +21.7% | – | |
| – | – | – | – | – | – | – | – | |
| – | – | – | -136.3% | +377.8% | -100.0% | – | – | |
| – | -55.6% | -40.8% | +942.5% | +258.8% | -96.4% | +949.4% | +44.5% | |
| – | -590.8% | – | +150.8% | +323.3% | -192.7% | – | – | |
| – | – | – | -316.0% | – | – | – | -1,418.5% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.